GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday. The move comes as a multi-state outbreak among livestock and poultry has caused several human infections,

EST: Adds comments from CSL The U.S. has reportedly awarded $72M to GSK (NYSE:GSK), Sanofi (NASDAQ:SNY), and CSL (OTCQX:CSLLY) to expand the production of bird flu vaccines amid an ongoing outbreak among poultry and livestock that has led to fears of a potential human-to-human transmission of the virus.

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird flu vaccines.

The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to help fortify the US supply of bird flu vaccine ahead of 2025. The funding was disclosed by the Administration for Strategic Preparedness and Response,

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.

US has announced team up with multinational pharmaceutical companies CSL, GSK, Sanofi, and Seqirus for a $72 million worth of bird flu vaccine production initiative.On Friday, October 4, the US Federal health officials announced that they will

The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising the country’s total supply of ready-to-use doses to 10 million within the f

As more farm workers get sick with avian influenza, the US federal government is putting $72 million toward strengthening its vaccine stockpile.